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INTRODUCTION
It is known that about one-third of deaths worldwide (i.e., ~17.3 
million per year) are caused by cardiovascular dysfunctions [1]. 
Among patients with cardiovascular disease, 30.7% of patients 
were found to have both hypertension and dyslipidemia, and 
66.3% of patients with diabetes had concomitant hypertension 
and dyslipidemia, in a 3-year retrospective study [2]. Thus, mul-
tiple drug therapy has been widely practiced for the treatment of 
problems including hypertension and dyslipidemia. Rosuvastatin, 
a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reduc-
tase inhibitor, is commonly used in combination with telmisar-
tan, an angiotensin II type-I receptor antagonist (ARB). Recently, 
Son et al. [3] reported increased pharmacokinetic (PK) exposure 
of rosuvastatin when coadministered with telmisartan. The ab-
sorption of rosuvastatin was accelerated (Cmax was doubled, with 
Tmax change from 5 h to 0.75 h.), whereas its AUC increased by 
only 1.18-fold when coadministered with telmisartan, although 
the cause of this phenomenon was not identified by the authors. 
In addition to the rosuvastatin–telmisartan interaction, it is 
well-known that cyclosporine also increases rosuvastatin AUC 
and Cmax by 1.5- and 3.0-fold and more severe interaction was 
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ABSTRACT It was recently reported that the Cmax and AUC of rosuvastatin increases 
when it is coadministered with telmisartan and cyclosporine. Rosuvastatin is known 
to be a substrate of OATP1B1, OATP1B3, NTCP, and BCRP transporters. The aim of 
this study was to explore the mechanism of the interactions between rosuvastatin 
and two perpetrators, telmisartan and cyclosporine. Published (cyclosporine) or 
newly developed (telmisartan) PBPK models were used to this end. The rosuvastatin 
model in Simcyp (version 15)’s drug library was modified to reflect racial differences 
in rosuvastatin exposure. In the telmisartan–rosuvastatin case, simulated rosuvas-
tatin CmaxI/Cmax and AUCI/AUC (with/without telmisartan) ratios were 1.92 and 1.14, 
respectively, and the Tmax changed from 3.35 h to 1.40 h with coadministration of 
telmisartan, which were consistent with the aforementioned report (CmaxI/Cmax: 2.01, 
AUCI/AUC:1.18, Tmax: 5 h → 0.75 h). In the next case of cyclosporine–rosuvastatin, the 
simulated rosuvastatin CmaxI/Cmax and AUCI/AUC (with/without cyclosporine) ratios 
were 3.29 and 1.30, respectively. The decrease in the CLint,BCRP, intestine of rosuvastatin 
by telmisartan and cyclosporine in the PBPK model was pivotal to reproducing this 
finding in Simcyp. Our PBPK model demonstrated that the major causes of increase 
in rosuvastatin exposure are mediated by intestinal BCRP (rosuvastatin–telmisartan 
interaction) or by both of BCRP and OATP1B1/3 (rosuvastatin–cyclosporine interac-
tion). 
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reported in transplant recipients (>6 months, stable heart trans-
plant recipients): the AUC and Cmax ratios of rosuvastatin (with/
without cyclosporine) were of 7.1- and 10.6-fold, respectively 
[4,5]. Cyclosporine is an inhibitor of many transporters including 
OATP1B1/1B3, NTCP, and BCRP transporters and the rosuvas-
tatin–cyclosporine interaction is known to be mediated by trans-
porters.
Telmisartan prevents angiotensin II from exerting its vaso-
constrictive effects on blood vessels, and thus has been widely 
used for the treatment of hypertension [6,7]. It has been reported 
that telmisartan is rapidly absorbed in the gastrointestinal tract 
(Tmax 0.75 h) [3] and is predominantly transported into the liver 
by organic anion transporting polypeptide (OATP) 1B3 [7], to be 
metabolized to an acylglucuronide conjugate by hepatic UDP-
glucuronosyltransferase (UGT) 1A3 [8], such that no unchanged 
parent molecule is excreted [9]. Recently, Hirano et al. [10] re-
ported that telmisartan potently inhibited OATP1B1-mediated 
pravastatin uptake (inhibitory constant (Ki), 0.436 µM) and 
OATP1B3-mediated dioscin uptake (Ki, 1.03 µM) in vitro [11]. 
In addition to uptake transporter inhibition, telmisartan is also 
known to be a non-specific inhibitor of ATP-binding cassette 
(ABC) transporters, such as P-glycoprotein (P-gp), breast cancer 
resistance protein (BCRP) [12], and multidrug resistance-associ-
ated protein 2 (MPR2) [13].
Rosuvastatin, a highly selective and competitive HMG-CoA re-
ductase inhibitor, reduces LDL and increases HDL cholesterol lev-
els in blood [14]. It is mainly excreted unchanged into bile [15,16], 
and less than 10% is metabolized to N-desmethylrosuvastatin by 
CYP2C9 [17]. Rosuvastatin is extensively distributed into the liver, 
presumably due to active uptake by OATP1B1 and OATP1B3, as 
well as by the sodium-dependent taurocholated co-transporting 
polypeptide (NTCP) transporters [18-20], despite its low passive 
diffusion into hepatocytes [4,15,21]. It is also a substrate of both 
liver canalicular and intestinal BCRP efflux transporters [21-23]. 
Nowadays, it has been reported that the increased rosuvastatin 
exposure by concomitant medication is mediated by the BCRP 
transporter, rather than by OATP1B1/1B3 transporters [24,25]. 
The aim of this study is to explore the mechanism of the trans-
port-mediated interaction between rosuvastatin and two perpe-
trators, telmisartan and cyclosporine. Although many research-
ers have reported that PK changes of rosuvastatin are mainly 
due to OATP1B1-mediated interactions, we demonstrate here 
that alterations in the PK of rosuvastatin upon coadministration 
with telmisartan are mainly mediated by their sharing BCRP, not 
OATP1B1/1B3, transporters, using a physiologically based PK 
(PBPK) model. We also describe rosuvastatin and cyclosporine 
DDI with PBPK model focusing on transporter-mediated interac-
tions. Moreover, because Asians show higher systemic exposure 
of rosuvastatin than Caucasians do [26,27], the PBPK model 
reflecting exposures in Koreans was applied to the rosuvastatin 
model. PBPK modeling provides a bottom-up approach to PK 
predictions with integration of diverse information on human 
physiology, physiochemical properties of drugs, and drug me-
tabolizing enzymes and transporters. Simcyp (version 15 release 
1, Certara, Sheffied, UK) was used in this report to explore the 
contributions of BCRP and OATP1B1/1B3 transporters to drug 
interactions and to predict the PK of rosuvastatin. 
A part of this paper was presented at the 11th international 
ISSX meeting (2016). A part of this study was first published as 
an original article in Biopharm Drug Dispos 2017; doi: 10.1002/
bdd.2060, but was retracted by the authors because trivial miscal-
culations incurred by one misused input parameter were found 
throughout the simulated values in the article. For further details, 
please read doi: 10.1002/bdd.2082.
METHODS
Development of the telmisartan model
Simcyp (version 15 release 1, Certara, Sheffield, UK) was used 
to simulate and predict the time course of rosuvastatin in plasma 
with or without telmisartan. The telmisartan model was devel-
oped based on the report by Li et al. [28], where many of the phys-
iochemical properties and in vitro PK parameters of telmisartan 
used herein are listed in Table 1. The simulation of telmisartan 
plasma concentration–time profiles was performed using a full-
PBPK model of first-order absorption. The ka and Fa values are 
from Li et al. [28], and the nominal flow in gut model (Qgut), 
which reflects both permeability through the enterocyte mem-
brane and villous blood flow [29], was estimated by Simcyp to be 
15.564 L/h based on telmisartan physiochemical properties. The 
human PET data-derived kp values [28] for adipose tissue, bone, 
brain, gut, heart, kidney, lung, muscle, skin, and spleen used in 
this study were 0.35, 0.47, 0.25, 1.67, 1.54, 4.4, 1.07, 0.40, 0.26, and 
0.41, respectively. However, we used the value reported by Rodg-
ers and Rowland (0.12) [28,30] for the hepatic kp because PET 
cannot discern telmisartan in hepatocytes from its metabolite, 
telmisartan-glucuronide, whose concentration is much higher 
than that of the parent compound in the liver [28]. The steady-
state volume of distribution (Vss) was then estimated as 0.41 L/kg 
based on the aforementioned kp values using mathematical model 
2 implemented in Simcyp [28]. For the telmisartan CLpo, the 
mean value reported in healthy subjects (25.2 L/h) was used [3]. 
Before the evaluation of telmisartan–rosuvastatin pharmaco-
kinetic interactions, a clinical trial simulation of telmisartan was 
performed with virtual healthy populations (aged 20-50, female 
ratio of 0.5) in 10 trials of 10 subjects each. Simulated PK param-
eters and concentration–time profiles of telmisartan after a single 
and multiple (80 mg) oral administration were compared with 
observed PK data for validation.
BCRP-mediated drug interaction model for rosuvastatin
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Modification of the rosuvastatin model
A PBPK model of rosuvastatin in a European Caucasian 
healthy volunteer population was previously constructed in 
Simcyp’s drug library. Because Asians show higher systemic 
exposure of rosuvastatin than do Caucasians [26], the recom-
mended starting dose for Asians (5 mg) is lower than that for 
Caucasians (10 mg) [27]. Although the cause of these racial differ-
ences is unclear, one possible explanation is that there may be dif-
ferences in the activity or expression levels of uptake transporters 
of rosuvastatin, such as OATP1B1, OATP1B3, and NTCP, and/
or an efflux transporter, such as BCRP. Because the PK data of a 
telmisartan–rosuvastatin interaction study conducted in Korean 
healthy volunteers were used as the reference [3], the rosuvastatin 
model in Simcyp’s drug library was modified to reflect PK pro-
files in Koreans. Using Sensitivity Analysis (SA) and Parameter 
Estimation (PE) modules, the hepatic uptake clearance values of 
OATP1B1, OATP1B3, and NTCP for rosuvastatin were modified 
step-by-step to recover the published mean plasma concentration-
time profile of rosuvastatin in Korean populations [3,31,32] from 
5 different studies, whose data were obtained by digitization (Plot 
Digitizer, version 2.6.6, http://plotdigitizer.sourceforge.net). After 
these modifications, rosuvastatin concentrations in 10 virtual 
trials (10 healthy subjects per trial, aged 20-50, male/female=1:1) 
after a single (20 mg) oral dose were simulated in Simcyp. 
Evaluation of the effects of telmisartan on the PK of 
rosuvastatin using PBPK modeling
Estimation of Ki,BCRP,intestine of telmisartan: Based on the above 
telmisartan and rosuvastatin models, telmisartan–rosuvastatin 
interaction was predicted. The in vitro inhibitory constants 
of telmisartan against hepatic OATP1B1 (Ki,OATP1B1,hepatic) and 
OATP1B3 (Ki,OATP1B3,hepatic) have been reported as 0.436 µM and 
1.03 µM, respectively [10,11]. Because there was no published 
Ki value of telmisartan against the intestinal BCRP transporter 
(Ki,BCRP,intestine), several methods were used to estimate the proper 
Ki,BCRP,intestine value of telmasartan; 1) its half-maximal inhibitory 
concentration (IC50,BCRP) [13] was used to calculate Ki,BCRP,intestine, by 
Eq. (1) described in [33]: 
 Ki=IC50/(1+S/Km) (1) 
where S is substrate concentration and Km represents the Mi-
chaelis–Menten constant of the substrate. If S is near Km values, 
then Ki,BCRP,intestine would be IC50/2. 2) In addition to using the esti-
mated Ki,BCRP,intestine value as IC50/2, a sensitivity analysis (SA) com-
paring simulated and observed Cmax and AUC ratios at varying 
Ki,BCRP,intestine estimates was conducted. 3) Based on the Ki,BCRP,intestine 
estimate obtained from SA, the parameter estimation (PE) mod-
ule was used for the estimation of the Ki,BCRP,intestine value.
Simulation of clinical study: Clinical trials in 100 virtual 
healthy subjects (10 trials×10 subjects per trial, aged 20-50, 
male:female=1:1) were simulated in Simcyp with a dosing scheme 
identical to that reported by Son et al. [3]. After rosuvastatin (20 
mg qd) was given alone or together with telmisartan (80 mg qd) 
for six days, plasma concentration profiles of rosuvastatin were 
simulated to compare with those reported elsewhere [3,32] (Table 
2). The profiles of rosuvastatin in the gut and liver were also pre-
dicted to elucidate the mechanisms of interaction. 
Evaluation of the effects of cyclosporine on the PK of 
rosuvastatin using PBPK modeling
The cyclosporine model reported by Jamei et al. [4] was used 
(Table 1). We validated the model using the data digitized from 
two different human studies [34,35] (Plot Digitizer, version 2.6.6, 
http://plotdigitizer.sourceforge.net). Clinical trials in 100 vir-
Table 1. Physiochemical and pharmacokinetic parameters of telmisartan and cyclosporine used in PBPK modeling
Parameters (unit) Telmisartan Reference Cyclosporinea
Molecular weight (g/mol) 514.62 1,202
logD7.4 2.5 [28] 2.96 (logP)
pKa 3.8 [28]
Compound type Monoprotic Acid [28] Neutral
B/P ratio 0.78 [9] 1.36
fu,plasma 0.005 [9] 0.0365
fu,liver 0.013 [28]
fu,gut 0.015 Predicted by Simcyp
Fa 0.72 [28] 0.857
ka (h
–1) 0.68 [28] 0.679
CLpo (L/h) 25.2 [3] 24.07 (CLiv)
Ki,OATP1B1, hepatic (µM) 0.436 [10] 0.014
Ki,OATP1B3, hepatic (µM) 1.03 [11] 0.007
Ki,BCRP (µM) 0.005 Estimated by Parameter Estimation 0.28
aAll data are from [4].
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tual healthy subjects (10 trials×10 subjects per trial, aged 20-50, 
male:female=1:1) were simulated for the evaluation of the effects 
of cyclosporine on rosuvastatin PK. The profiles of rosuvastatin 
(20 mg) PK were simulated with or without cyclosporine (200 mg, 
BID). 
RESULTS 
Development of the telmisartan model
Telmisartan plasma concentration–time profiles after single 
oral administration (80 mg) were simulated using its physico-
chemical parameters and PK parameters (Table 1). The Cmax, 
AUC, and Tmax after administration of telmisartan 80 mg pre-
dicted by Simcyp (10 trials of 10 subjects each) were similar to the 
published data [6,36,37] and the simulation results of multiple ad-
ministrations of telmisartan 80 mg for 6 days also well explained 
the observed data (Fig. 1) [3,38,39].
Modification of the rosuvastatin model
The rosuvastatin model in the Simcyp drug library was modi-
fied by the authors to reproduce the Cmax and AUC in Koreans, 
which are about twice as high as in Caucasians [19,40]. The 
total CLint, uptake transporters value estimated using the SA method 
was adjusted for the ratio of CLint,hepatic,NTCP, CLint,hepatic,OATP1B1, and 
CLint,hepatic,OATP1B3 in Caucasians in Simcyp. The final CLint values 
were determined by the PE method using observed data from 5 
different studies in Koreans. Upon comparing the PK data re-
ported from Koreans [3,31,32] with our Simcyp-simulated ones, 
the CLint values of the hepatic uptake transporters of rosuvastatin 
were adjusted (Table 3): they were about 1/5 of CLints of Euro-
pean Caucasians (Pre-existing CLint,hepatic,NTCP, CLint,hepatic,OATP1B1, 
and CLint,hepatic,OATP1B3 values of 78, 109, and 36 µl/min/106 cells 
in Simcyp were modified as 19.7, 25.1, and 7.5 µl/min/106 cells, 
respectively, to be used for our simulation.). The Cmax, AUC, and 
Tmax of rosuvastatin (20 mg single oral dosing) simulated using 
the modified CLints of uptake transporters were 25.7±10.1 ng/ml, 
235±95.2 ng h/ml, and 3.30 (1.92-3.85) h, respectively (Fig. 2). 
Evaluation of the effect of telmisartan on the PK of 
rosuvastatin using PBPK modeling
Prior to conducting the simulation of drug–drug interaction 
studies, the Ki,BCRP,intestine of telmisartan was estimated. We ini-
tially tried IC50,BCRP/2 (8.45 µM) using Eq. (1) as the Ki,BCRP,intestine 
of telmisartan. However, the AUCI/AUC and CmaxI/Cmax of rosu-
vastatin (with/without telmisartan) predicted thereby were both 
1.00-fold which implied that the calculated Ki,BCRP,intestine (8.45 µM) 
Table 3. The summary of hepatic uptake clearances of rosuvas-
tatin modified using clinical data in Koreans
Parameters 
(µl/min/106 cells)
In Simcyp  
drug’s library 
(Caucasian)
After 
modification  
with clinical data
CLint,hepatic,NTCP 78 19.7
CLint,hepatic,OATP1B1 109 25.1
CLint,hepatic,OATP1B3 36 7.5
Fig. 1. Simulated and observed plasma telmisartan concentration–
time profiles after a single and multiple (for 6 days) oral adminis-
tration of 80 mg telmisartan. Solid line and dashed lines represent 
mean and 95th and 5th percentiles of simulated telmisartan concentra-
tions and dots are observed data from references [8,36,37] for a single 
and [3,38,39] for multiple dosing, respectively.
Table 2. Observed and simulated (PBPK modeling) rosuvastatin pharmacokinetic (20 mg, multiple doses) exposures 
Rosuvastatin exposure parameters Cmax (ng/mL) AUC (ng h/mL) Tmax
 (h)a CmaxI/Cmax AUCI/AUC
Observedb Without perpetrators 27.8 229 5.00
With telmisartan 56.0 270 0.75 2.01 1.18
Predictedc Without perpetrators 24.4 (22.5-26.5) 226.0 (208.3-245.1) 3.35
With telmisartan 46.9 (42.6-49.8) 257.6 (238.6-277.3) 1.40 1.92 1.14
With cyclosporine 80.3 (74.4-86.6) 293.4 (271.5-317.1) 1.00 3.29 1.30
aTmax’s are expressed as medians.
bSon et al., 2014 [3]; Cmax and AUC are expressed as geometric means.
cCmax and AUC are expressed as geometric mean (95% prediction interval).
BCRP-mediated drug interaction model for rosuvastatin
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as half the IC50,BCRP (16.9 µM) [13] under-predicted the magnitude 
of the rosuvastatin–telmisartan interaction. Thus, we carried 
out SA of Ki,BCRP,intestine. The Ki,BCRP,intestine chosen from SA (0.003 
µM) was much lower than 8.45 µM, that obtained from IC50,BCRP 
and this was used as the as the initial value for the PE module. 
The final estimate of Ki,BCRP,intestine obtained from the PE module 
(0.005 µM) best explained the observed drug interactions. Thus, 
this Ki,BCRP,intestine value was chosen to be employed in the rosuv-
astatin–telmisartan interaction study. Assuming that the affinity 
of BCRP present in the liver and intestine are the same, we also 
implemented this value to account for the possible inhibition of 
BCRP transporter existing in hepatocytes.
After the simulation of clinical studies, the predicted changes 
in plasma concentration–time profiles of rosuvastatin upon co-
administration of telmisartan are overlaid with reported data in 
Fig. 3. The observed and predicted Cmax, Tmax, and AUC of 20 mg 
rosuvastatin with or without coadministration of 80 mg telmis-
artan are listed in Table 2. The predicted AUCI/AUC (1.14) and 
CmaxI/Cmax (1.92) of rosuvastatin were similar to those reported by 
Son et al. (AUCI/AUC 1.18 and CmaxI/Cmax 2.01) [3]. The changes in 
gut and liver rosuvastatin concentrations were predicted to eluci-
date the intestinal BCRP-mediated interactions. In the GI tract, 
telmisartan increased the enterocyte concentration of rosuvas-
tatin by 2.20-fold (Fig. 4, the representative intestinal segment, je-
junum), that indicated the inhibition of BCRP efflux transporter 
by telmisartan. Extracellular and intracellular concentrations 
of rosuvastatin in liver were also available in these models (Fig. 
5). Changes in the extracellular and intracellular rosuvastatin 
concentration-time profiles of rosuvastatin by telmisartan were 
almost identical (accelerated Tmax and increased Cmax), thus the ex-
tracellular/intracellular AUC ratio of rosuvastatin did not change 
at all (0.203 without telmisartan versus 0.201 with telmisartan). 
Moreover, the change in sinusoidal uptake clearance of rosuv-
astatin is insignificant. These results also imply that the hepatic 
transporter-mediated interaction by telmisartan is negligible.
Evaluation of the effect of cyclosporine on the PK of 
rosuvastatin using PBPK modeling
The simulated whole blood concentration–time profiles of cy-
closporine after 200 mg BID oral administration well explained 
the observed data (Fig. 6B). The predicted changes of plasma ex-
posures of rosuvastatin are shown in Fig. 6A and the PK parame-
ters are listed in Table 2. The changes in gut and liver rosuvastatin 
concentrations were also estimated in this simulation. The pre-
dicted enterocyte concentrations of rosuvastatin in the presence 
of cyclosporine were 3.27-fold higher than those of rosuvastatin 
alone. In hepatocytes, the extracellular/intracellular AUC ratio of 
rosuvastatin was predicted to increase by 22.7% by cyclosporine 
(0.203 without cyclosporine versus 0.249 with cyclosporine) and 
this implied that both of BCRP and OATP1B1/3-mediated inter-
actions by cyclosporine play an important role in rosuvastatin 
disposition. The change in sinusoidal uptake clearance of rosuv-
astatin by cyclosporine appeared significant compared to that by 
telmisartan (Fig. 5B).
Fig. 3. Simulated and observed plasma concentration–time pro-
files of rosuvastatin in rosuvastatin–telmisartan study. Plasma 
concentrations of rosuvastatin (time after the last dose, 0-24 h) were 
simulated after 20 mg of rosuvastatin was orally coadministered with 
(black solid line) or without (blue solid line) 80 mg telmisartan for 6 
days. The dashed lines represent the upper (95%) and lower (5%) per-
centile concentrations of rosuvastatin, respectively. Observed data are 
from references [3,32].
Fig. 2. Simulated and observed plas-
ma concentration–time profile of 
rosuvastatin after a single oral admin-
istration of 20 mg rosuvastatin. Simu-
lated concentration profiles of 10 trials 
are represented by solid lines (mean) 
and dashed lines (95th and 5th percen-
tiles). (A) Simcyp library model (based on 
Caucasian data), (B) our model modified 
using clinical (Korean) data listed in Table 
3. Observed data are from references 
[3,32].
BA
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DISCUSSION
This study primarily aimed to demonstrate that the BCRP-
mediated drug interactions are critical in rosuvastatin by pre-
senting two example cases. The first case is the rosuvastatin–
telmisartan study. The primacy of the contribution of the 
intestinal BCRP transporter seems to be in accord with the PK 
characteristics of telmisartan and rosuvastatin. Telmisartan (Tmax 
0.75 h) is absorbed faster than rosuvastatin (Tmax 5 h), presum-
ably due to its highly permeable absorption in the GI tract. The 
Simcyp-predicted intestinal tissue concentration of telmisartan 
multiplied by fu,gut (0.015) increased above its Ki,BCRP, intestine (0.005 
µM) immediately after administration, and was maintained for 
about 9 h (data not shown). In other words, Simcyp predicted that 
telmisartan pre-occupied the binding sites of intestinal BCRP 
owing to its faster absorption characteristic, before rosuvastatin 
molecules could engage with the BCRP transporters, resulting in 
its accelerated absorption (Cmax↑, Tmax↓) without evident decrease 
in systemic clearance. Mixed-effects modeling results also sup-
ported that the rosuvastatin population PK parameter changes by 
telmisartan implied a modest increase (1.3-fold) in relative bio-
availability despite the drastic acceleration of the absorption rate 
[32]. 
The second case is the rosuvastatin–cyclosporine study which 
supports the view that both of the BCRP and OATP1B1/3 trans-
porters contribute to the increased exposure of rosuvastatin. 
Unlike the rosuvastatin–telmisartan case, hepatic OATP1B1/3-
mediated interactions were crucial because cyclosporine ex-
hibited more potent inhibitory effects (Ki, OATP1B1=0.014 µM, Ki, 
OATP1B3=0.007 µM) against OATP1B1/3 than telmisartan did (Ki, 
OATP1B1=0.436 µM, Ki, OATP1B3=1.03 µM). This enabled cyclosporine 
to reach concentrations sufficient to inhibit OATP1B1/3 at the 
target site. Reproduced cyclosporine PBPK model well explained 
the observed data and the simulation results were also accordant 
Fig. 4. Predicted enterocyte concentration of rosuvastatin in the 
jejunum I, a representative GI segment.
Fig. 6. Simulated plasma concentra-
tion–time profiles of rosuvastatin in 
rosuvastatin–cyclosporine study (A) 
and simulated vs. observed whole 
blood exposures of cyclosporine (B). 
The dashed lines represent the upper 
(95%) and lower (5%) percentile concen-
trations of rosuvastatin (A) and cyclo-
sporine (B). Dots are observed data from 
references [34,35].
BA
Fig. 5. Predicted hepatic unbound 
extracellular water concentration 
(CuEW, lower black lines) and hepatic 
unbound intracellular water concen-
tration (CuIW, upper blue lines) of ro-
suvastatin (A) and sinusoidal uptake 
clearance of rosuvastatin (B).
BA
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with those in Jamei’s report [4].
The changes in gut and liver rosuvastatin concentration pro-
files were also predicted in our study. Using the Advanced Disso-
lution, Absorption and Metabolism (ADAM) model implemented 
in Simcyp, changes in rosuvastatin concentration in each segment 
were predicted. In the representative intestinal segment (jejunum), 
one of the segments where the BCRP transporters are abundantly 
expressed [41], the rosuvastatin exposure in enterocytes was 
2.20-fold and 3.27-fold higher in the presence of telmisartan and 
cyclosporine, respectively (Fig. 4, patterns in the other segments 
were similar: data not shown), supporting the hypothesis that the 
BCRP transporter is a major cause of drug interactions of rosuv-
astatin in both cases. 
Increased absorption of rosuvastatin by telmisartan and cy-
closporine has driven a greater fraction of rosuvastatin to reach 
the liver and caused accelerated Tmax and increased Cmax in both 
extracellular water and intracellular water of hepatocytes. How-
ever, there are critical differences in two cases. In the case of 
telmisartan interactions, it is of note is that the hepatic uptake of 
rosuvastatin was increased by telmisartan without a change in 
extracellular water/intracellular water rosuvastatin AUCs, despite 
its known inhibition of OATP1B1/1B3 transporters (Ki,OATP1B1/
OATP1B3, hepatic values of 0.436 and 1.03 µM, respectively) [10,11]. On 
the contrary, in the case of cyclosporine interactions, extracellu-
lar/intracellular rosuvastatin AUC ratios in hepatocytes increased 
by 22.7% in the presence of cyclosporine, which indicated that ro-
suvastatin uptake into the hepatocyte was reduced. Similarly, pre-
dicted sinusoidal uptake clearance of rosuvastatin did not change 
in the presence of telmisartan whereas that of rosuvastatin was 
reduced in the presence of cyclosporine (Fig. 5B). 
There is another report supporting this inference. Gemfibrozil 
inhibits OATP1B1-, OATP2B1-, and NTCP-mediated rosuvastatin 
uptake [20]. In a gemfibrozil–rosuvastatin interaction study in 
humans, the AUC and Cmax of rosuvastatin were doubled, whereas 
those of the metabolite, N-desmethyl rosuvastatin, were halved 
[42]. This implies that gemfibrozil inhibited rosuvastatin uptake 
into hepatocytes, resulting in the decreased N-desmethylation of 
rosuvastatin by CYP2C9 in hepatocytes. On the other hand, the 
AUC and Cmax of N-desmethyl rosuvastatin increased by 1.07- 
and 1.53- fold, respectively, with coadministration of telmisartan 
in Son’s report [3], which was the opposite of the results of the 
gemfibrozil-rosuvastatin study. Thus, the mechanistic explana-
tion of the interaction between rosuvastatin and telmisartan 
proposed in this report is: telmisartan inhibits rosuvastatin efflux 
in the GI tract → the amount of rosuvastatin absorbed into the 
portal vein is increased → the hepatic uptake of rosuvastatin is 
increased.
To determine the Ki,BCRP,intestine value of telmisartan, we em-
ployed a top-down approach using data from five different clini-
cal DDI studies. It is known that some discrepancy exists between 
in vitro and in vivo Ki values as exemplified by Kato et al. [43]. 
Because the in vitro Ki,BCRP,intestine value under-predicted the effect 
of telmisartan on the rosuvastatin exposures observed in clinical 
trials, we decided to use a top-down approach. Hu and his col-
leagues performed an in vitro transporter interaction study with 
telmisartan and rosuvastatin [25]. Their result was that the efflux 
ratio of rosuvastatin significantly decreased by 42% by 1 µM of 
telmisartan and this was consistent with our results.
We used in vivo CLpo rather than metabolic clearance in he-
patocytes (CLint, met) for the telmisartan CL in the simulation step 
for the following reasons: 1) an in vivo CLpo value (25.2 L/h) was 
suitable to recover the observed telmisartan PK; 2) the metabolic 
pathway of telmisartan in hepatocytes did not overlap that of 
rosuvastatin; and 3) the half-life of telmisartan is over 20 h [9] 
despite the CLint,met of telmisartan being reported as 395 µl/min/
mg microsomal protein [44] or 1,210 µl/min/mg microsomal 
protein [28] belonging to high extraction ratio drugs. The dis-
crepancy between CLint,met and in vivo CLpo can be explained by 
the enterohepatic circulation of telmisartan-glucuronide after 
biliary excretion and deconjugation in the intestine [8,28]. Failure 
to reflect the reabsorbed portion of telmisartan can result in over-
estimation of CLint,all, leading to overestimation of CLH, and ulti-
mately, of CLin vivo. Because there is no quantitative information 
on biliary-excreted and recirculated telmisartan and its glucuro-
nide, our model did not address the enterohepatic recirculation of 
telmisartan.
To reproduce rosuvastatin exposure in healthy Korean subjects, 
the CLint values of uptake transporters were modified. In Asian 
subjects, the exposure of rosuvastatin is known to be almost twice 
that in Caucasians [27]. This has been suggested to be due to a 
race-related difference in CLH, but not in CLR or FaFg [45]. OAT-
P1B1 (SLCO1B1) has single-nucleotide polymorphisms (SNPs) of 
T521>C (Val174Ala) and A388>G (Asn130Asp) associated with 
the OATP1B1 *1a (174Val and 130Asn), *1b (174Val and 130Asp), 
*5 (174Ala and 130Asn), and *15 (174Ala and 130Asp) alleles [46], 
which cause genetic variability in rosuvastatin PK. However, it 
does not explain the race-related variability of rosuvastatin PK. 
The allelic frequency of 521T<C, which is closely correlated with 
rosuvastatin PK, is similar between Asians and Caucasians [21,47]. 
Despite the SLCO1B1 genotype being identical between Cauca-
sians and Chinese, the Cmax and AUC of Chinese were approxi-
mately twice those of Caucasians [21,40]. Based on these reports, 
Tomita et al. [45] suggested that there may be a difference in pro-
tein expression levels of hepatic OATP1B1 between Asians and 
Caucasians. The effect of the genetic polymorphism of OATP1B3 
and NTCP on the racial differences in rosuvastatin PK is unclear. 
Similar to the case of rosuvastatin, pravastatin, another substrate 
of OATP1B1, showed higher exposure in Asians as well. Li et al. 
tried to explain this with the OATP1B1 genetic variant, however, 
more supporting evidences are needed to apply their assertion for 
PBPK models [48].
A few reports [40,49,50] suggested that the genetic polymor-
phism of BCRP may have caused inter-racial difference in rosu-
vastatin exposure, but more studies are needed to conclude this. 
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Considering the degree of uncertainty with respect to uptake 
transporter-mediated racial differences, CLint values of hepatic 
uptake transporters had to be adjusted based on the observed ro-
suvastatin systemic exposures, which is a limitation of our model. 
Therefore, quantitative prediction of drug interaction potential 
for telmisartan as an intestinal BCRP inhibitor in this report may 
be reproduced in other races if appropriate clinical and/or in vitro 
data are available. 
In conclusion, our PBPK modeling to evaluate rosuvastatin–
telmisartan/cyclosporine interaction revealed that the intestinal 
BCRP transporter is a major contributor to the interactions.
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